Table 4.

The characteristics and outcome of the CML patients with COVID-19 patients according to the TKI they received.

Characteristics	CML-imatinib(n = 9)	CML-nilotinib(n = 3)	CML-dasatinib(n = 4)	P value
Gender
Male	5 (55,5%)	0	1 (25%)	0,2
Female	4 (45,5%)	3 (100%)	3 (75%)
Age (years)	46 (27–62)	52 (47–87)	53 (50–80)	0,2
Comorbidity
Hypertension	3 (33,3%)	1 (33,3%)	3 (75%)	0,7
Diabetes mellitus	2 (22,2%)	0	1 (25%)	0,4
Cardiovascular diseases	2 (22,2%)	1 (33,3%)	2 (50%)	0,6
Respiratory system diseases	2 (22,2%)	1 (33,3%)	1 (25%)	0,9
Chronic renal diseases	2 (22,2%)	0	0	0,4
Cerebrovascular diseases	0	0	1 (25%)	0,2
Additional treatment, n (%)
Favipiravir	3 (33,3%)	1 (33,3%)	0	0,4
Oseltamivir	5 (55,5%)	2 (66,6%)	2 (50%)	0,9
Lopinavir/ritonavir	0	1 (33,3%)	0	0,1
Hydroxychloroquine	8 (88,8%)	2 (66,6%)	3 (75%)	0,7
High dose Vitamin C	1 (11,1%)	0	0	0,7
ICU admission, n (%)	0	0	1 (25%)	0,2
MV, n (%)	0	0	1 (25%)	0,2
Duration in hospital, days	8 (6–18)	12,5 (12–3)	5,5 (2–9)	0,4
Duration in ICU, days	0	0	1 (25%)	0,2
CFR, n (%)	0	0	1 (25%)	0,2

CFR: case fatality rate; CML: chronic myeloid leukemia; ICU: intensive care unit; MV: mechanical ventilation.